Cambridge, Massachusetts-based ImmusanT, a developer of treatments for celiac disease, has closed $40 million in Series C financing. The investors were ARCH Venture Partners and Vatera Healthcare Partners. In conjunction with the funding, Dr. Steven Gillis and Dr. Thomas Daniel have joined ImmusanT’s board of directors. MTS Health Partners LP served as the adviser on the transaction.
Source: Press Release